Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours by Parliament, M B et al.
Among the various adaptive responses to cell and tissue hypoxia is
that of neoangiogenesis. This process occurs under physiological
and pathophysiological conditions. It is becoming apparent that
primary brain tumours of astrocytic lineage, especially glioblas-
toma multiforme, exhibit hypoxia-induced neoangiogenesis in
vivo through induction of the endothelial cell-specific mitogen,
vascular endothelial growth factor (VEGF) (Shweiki et al, 1992;
Plate et al, 1992, 1994). A strong correlation was found between
intense VEGF expression and severe hypoxia in situ in HT29 and
EMT-6 spheroids (Waleh et al, 1995).
Recently we have observed variable presence of hypoxia adja-
cent to necrosis in some xenografted glioma lines and spheroids
(Parliament et al, 1997; Franko et al, 1998). The results were inter-
preted in terms of regional variations in oxygen consumption,
based on the concept of modulation of oxygen consumption in
regions of oxygen and nutrient deprivation in solid tumours
(Hochachka et al, 1996). We were interested in determining the
pattern of VEGF expression in situ, particularly in the nutrient-
deprived regions of viable cells adjoining necrosis, which may or
may not be severely hypoxic in human glioma spheroids and
xenografts. We recently showed that the M006XLo line has
elevated expression of VEGF under aerobic conditions, with
modest hypoxic induction compared to the M006X line (Allalunis-
Turner et al, 1999). In this report we have examined the oxygen
dependence of VEGF mRNA expression in the M006X line under-
going mild hypoxic stress (6% oxygen (O2)), and we have also
examined VEGF expression in spheroids of both M006X and
M006XLo lines and in xenograft tumours of the M059K, M006
and M010b lines. We also sought to independently validate the
presence of radiobiologically hypoxic cells in situ in M006
tumours using the comet assay of in-situ DNA damage (Olive et
al, 1997, 1998).
Finally, we have performed preliminary experiments to assess
the presence of tumour-cell VEGF receptor (Vaisman et al, 1990)
expression which has previously been seen in melanoma and
ovarian carcinoma lines (Boocock et al, 1995; Liu et al, 1995),
suggesting autocrine/paracrine growth stimulation.
MATERIALS AND METHODS
Cell lines, spheroids and xenografts
Details of the origin and characterization of the glioma cell lines
used in this study have been previously published (Parliament
et al, 1997; Allalunis-Turner et al, 1991). The M0059K (passage
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of grade 4 astrocytomas; the M010b (passage 44) line was derived
from a grade 3 anaplastic astrocytoma. The M006X (passage 131)
subline was derived from a xenografted M006 tumour growing in
a severe combined immunodeficient (SCID) mouse and disaggre-
gated by mechanical and enzymatic methods as described previ-
ously (Parliament et al, 1997). M059KX (passage 165) and
M010bX (passage 54) sublines were similarly derived from
xenografts originating from the M059K and M010b lines respec-
tively. The M006XLo subline was established from M006
spheroids (passage 129) which had been exposed continuously to
0.6% oxygen for 13 days, beginning 1 week after initiation in air.
The spheroids were disaggregated with 0.25% trypsin, and the
cells were grown in monolayer culture for four passages
(5 weeks), and injected subcutaneously (s.c.) in SCID mice. One
tumour was disaggregated to yield a new line designated
M006XLo, which was propagated in monolayer culture
(Parliament et al, 1997). Details of the initiation and growth of
spheroids were as described in Franko et al (1998). M006XLo,
M006X, M059K and M010b tumours were raised s.c. in the flanks
of NOD/SCID mice. Details of the initiation and growth of tumour
xenografts were as described in Parliament et al (1997). All animal
experiments were performed according to guidelines for the use of
animals in research established by the Canadian Council for
Animal Care.
Northern blotting
Glioma cells were grown as monolayers under standard incubator
conditions (37°C, 5% carbon dioxide–95% air). To study the effect
of changes in the gas-phase O2 concentration on VEGF expres-
sion, a gas exchange manifold system utilizing a series of
leakproof aluminium chambers (Koch et al, 1979) was used to
create atmospheres of varying proportions of oxygen in 5% carbon
dioxide–95% N2. Total RNA was isolated from cells cultured for
24 h under aerobic or hypoxic conditions using the guanidinium–
silica gel column method (Qiagen). Twenty micrograms of total
RNA were electrophoresed in each lane. After transfer, the blots
were hybridized with 32P random-labelled probes to b-actin (gift
from Dr Roseline Godbout) or VEGF (gift from Dr Harold
Dvorak). The 204-bp human VEGF probe was originally prepared
by reverse transcription polymerase chain reaction (RT-PCR) with
oligonucleotide primers [(forward): 5¢-CGCGGATCCAGGAG-
TACCCTGATGAG-3¢; (reverse) 5¢-CCGGAATTCACATTTGT-
GTGCTGT-3¢] based on the human VEGF sequence (Berse et al,
1992). This probe recognizes all VEGF transcripts and does not
discriminate among alternatively spliced transcripts (Berse et al,
1992). To quantify changes in VEGF mRNA expression, the
autoradiograms which detected 32P decay were scanned using a
PDQUEST densitometer (pdi Inc., Huntington Stn, NY, USA).
Optical densities of the regions of the VEGF and b-actin bands
were determined using pdi Quantity One® scanning and analysis
software. VEGF mRNA optical densities were normalized using
b-actin mRNA of each sample as a control. Increases in mRNA
following exposure to hypoxic conditions were expressed as a
proportion of the aerobic (18% O2) culture expression levels.
Comet assay
Unanaesthetized NOD/SCID mice bearing M006 tumours were
used for experiments when the tumours reached a size of
300–500 mg. Mice were restrained in lucite jigs and breathed
room air. The tumours were irradiated with 15 Gy 250 kV X-rays
at a dose rate of 3.3 Gy min–1. Tumours were excised within 30 s 
at the end of radiation exposure and disaggregated in ice-cold
phosphate-buffered saline (PBS). Cell suspensions were mixed
with agarose (final concentration 0.75%), lysed with an alkaline
high salt lysis solution, rinsed in alkali, and exposed to 0.6 volts
cm–1 in an electrophoresis chamber as previously described (Olive
et al, 1997). DNA was stained with propidium iodide and indi-
vidual cell ‘comets’ were viewed using a Zeiss epifluorescence
microscope attached to an intensified solid state charge device
camera and image analysis system (Olive et al, 1997). The
hypoxic fraction was estimated by iterative fitting of histograms of
‘tail moment’ (product of the percentage of DNA in the comet tail
multiplied by the distance between the means of the head and tail
distributions) with two normal distributions, representing the
aerobic and hypoxic populations as described previously (Olive
et al, 1997).
Histologic preparation
After growth to diameters of 800–1000 mm spheroids of the M006
and M006XLo lines were labelled under aerobic conditions with
50 mM 3H-misonidazole for 3 h as described previously (Franko et
al, 1998). The specific activity of 3H-misonidazole was 1.045 ´
1010 Bq mol–1. Tumours were labelled with 3H-misonidazole with
three injections (of the same specific activity drug as noted above)
at 1-h intervals into mice at a dose equivalent to a whole body
concentration of 50 mM, as described previously (Parliament et al,
1997). The spheroids and tumours were either fixed in 10%
buffered formalin at 4°C overnight, then at room temperature for
at least 3 days, or fixed in methanol–chloroform–glacial acetic
acid (6:3:1 by volume; methanol-Carnoy’s) at 4°C for 30 min, then
overnight at room temperature. The material was then embedded
in wax, cut at 5 mm and mounted on poly-L-lysine-coated slides.
VEGF ISH
The human VEGF 204 bp probe described above was labelled
with biotin using a T7 RNA polymerase using biotin-14-CTP
(Gibco-BRL) according to manufacturer’s instructions. Spheroid
and xenograft (M006X) sections, which had been fixed with
formalin, were dewaxed and blocked with levamisole to block
detection of endogenous biotin. In situ hybridization (ISH)
detection utilized streptavidin linked to NBT (Oligo Colour Kit,
Amersham Life Sciences). Semi-quantitative assessment (after
Plate et al, 1994) of blue colour reaction was undertaken and
compared to 3H-misonidazole autoradiography on serial sections
(see below). The blue colour intensity was graded by one observer
as: (–) = absent; (+) = light; (++) = moderate; (+++) = heavy; and
(++++) = very heavy.
VEGF immunohistochemistry
Deparaffined slides underwent unmasking with hot citric acid
(2.1 g L–1 at pH 7.3 for 30 min at 70°C), then were rinsed with
PBS containing 10% goat serum. Slides were then incubated with
the primary rabbit anti-human VEGF antibody, 1:150 (Santa Cruz
A-20 raised to amino acid residues 1–20, recognizing VEGF 121,
165, 189 splice variants). The primary antibody was detected
using a Fast Red detection kit (BioGenex). Slides were lightly
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immunohistochemistry (IHC) staining. On control slides, the anti-
body was neutralized by incubation with a tenfold excess of
control VEGF peptide (Santa Cruz P-20) prior to the anti-VEGF
step. Additional controls in preliminary experiments used rabbit
IgG in place of the primary antibody.
3H-misonidazole autoradiography
Sections adjacent to those used for ISH and IHC were dewaxed,
dipped in NTB-2 emulsion and exposed for 4–6 weeks. After
developing and fixing, the sections were stained through the emul-
sion with haematoxylin and eosin. Grain density was counted
regionally at 10003 using a 10 ´ 10 mm microscope grid.
VEGF receptor (flt-1) IHC
M006XLo slides were prepared as for VEGF IHC. These slides
were then incubated with a polyclonal rabbit anti-human flt-1 anti-
body (Santa Cruz). The primary antibody was detected with the
Fast Red detection kit (BioGenex).
RESULTS
Northern blotting
Northern blot analysis of VEGF mRNA expression in M006X
cells incubated at various O2 concentrations is shown in Figure 1.
VEGF expression increased markedly with exposure to increasing
degrees of hypoxia. Levels of b-actin mRNA were comparable at
18, 6 and 2% O2, and were slightly decreased under anoxia.
Normalizing the (VEGF/actin) ratio in room air to unity, the
degree of VEGF induction observed under 6% O2, 2% O2, and
anoxia (100% N2) was as follows: 3.7-, 9.5-, and 29.8-fold respec-
tively.
Hypoxic fraction of M006 xenografts measured using
the comet assay
In 12 tumours from air-breathing mice, the mean hypoxic fraction
was 8.9 ± 7.0%, (range 0–21%). These results are summarized in
Table 1.
Relationship of VEGF mRNA expression to hypoxia
marker binding in glioma spheroids and xenografts
Aerobic M006XLo spheroids (Figure 2) and M006X spheroids
showed strong staining for the hybridized VEGF probe across the
entire viable rim. Semiquantitative assessment of ISH staining was
made and compared with the intensity of 3H-misonidazole
labelling on contiguous 5-mm sections (Table 2). Heterogeneity of
3H-misonidazole labelling adjacent to necrosis was seen from
spheroid to spheroid within the same experimental flask as
reported previously (Franko et al, 1998). Some spheroids
displayed heavy labelling in the inner five cell layers adjacent to
necrosis, indicating a substantial gradient of [O2], and severe
hypoxia adjacent to necrosis, while others were more lightly
labelled indicating aerobic levels of oxygen throughout the
spheroids (Franko et al, 1998). There was no apparent relationship
between VEGF expression and hypoxic marker binding, although
in one of ten spheroids, elevated 3H-misonidazole binding and
VEGF ISH staining were seen to co-localize to the innermost cells.
A similar relationship between VEGF and hypoxia marker binding
existed in M006X spheroids, which show lower levels of aerobic
expression of VEGF in vitro than the M006XLo line (data not
shown).
VEGF expression in human glioma 637
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Figure 1 Northern blot analysis of VEGF mRNA expression in M006X cells.
Total RNA was isolated from cells incubated for 24 h under various oxygen
concentrations as follows: lane 1, 18% O2; lane 2, 6% O2; lane 3, 2% O2;
lane 4, nitrogen
Table 1 Hypoxic fraction of M006 glioma xenograft tumours measured
using the comet assay
Tumour number Treatment Proportion of hypoxic cells
(curve fitting)
1 Air-breathing 0.10
2 Air-breathing 0.034
3 Air-breathing 0.01
4 Air-breathing 0
5 Air-breathing 0.137
6 Air-breathing 0.042
7 Air-breathing 0.071
8 Air-breathing 0.21
9 Air-breathing 0.107
10 Air-breathing 0.075
11 Air-breathing 0.067
12 Air-breathing 0.21
13 Clamped 0.81
Mean ± SD Air-breathing 0.089 ± 0.07
Figure 2 VEGF ISH from M006XLo spheroid (103)VEGF ISH in M006X tumours showed uniform staining in all
tumours examined except one, where there was increased staining
adjacent to approximately 20% of necrotic regions (Figure 3A,
43; Figure 3B 103). Five tumours were assessed, with identical
findings. Similar findings were also noted for M006XLo (two
tumours), M010bX (one tumour) and M0059KX (two tumours).
VEGF IHC
Immunoreactivity to the anti-VEGF antibody was superior for
tumours and spheroids fixed with methanol-Carnoy’s compared to
those fixed with formalin. The staining was more intense and the
concentration difference between non-specific staining with
control IgG and acceptable staining with the antibody was at least
threefold better for methanol-Carnoy’s. Control sections in which
the primary anti-VEGF antibody was neutralized by a large excess
of control VEGF peptide were uniformly negative. In all tumours
assessed of the M059KX, M006X, M006XLo and M010bX lines
(four tumours from each), and in M006XLo spheroids, immunode-
tection of VEGF protein showed similar staining across all regions
of healthy cells up to the border of necrosis (Figure 4A). In prelim-
inary experiments which used a wide range of dilution of the
primary antibody, the lightest staining visible appeared to be simi-
larly uniform, with no suggestion of preferential staining of cells
adjacent to necrosis. On contiguous sections, simultaneous assess-
ment of hypoxia marker binding indicated marked heterogeneity,
consistent with previous studies (Parliament et al, 1997). These
tumour regions included cells exhibiting a full range of 3H-
misonidazole grain densities (from fully aerobic to hypoxic). A
similar result was apparent using formalin-fixed tissue (data not
shown). These results indicate an absence of a correlation in situ
between [O2] and VEGF protein expression.
VEGFR (flt-1) IHC
Using a similar protocol to detect VEGFR (flt-1) in M006XLo
cells, we observed strong immunostaining for flt-1 in all tumour
cells of this preparation (Figure 5).
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Table 2 3H-miso autoradiography vs VEGF ISH in M006XLo glioma spheroids
Spheroid number 3H-miso grain densitya VEGF ISH intensityb
Outer layers Inner layers Outer layers Inner layers
1+ + + +
2+ + + +
3 + + ++ +++
6 + + +++ +++
10 + + ++++ +++
4 + ++ ++ ++
5 + ++ +++ ++
8 + +++ + ++
9 + +++ +++ ++++
aEach extra (+) indicates an increase in grain density by a factor of approximately 8. bIntensity was graded by one
observer as (–) = absent; (+) = light; (++) = moderate; (+++) = heavy; (++++) = very heavy.
N
N
Figure 3 VEGF ISH in M006X xenograft (43). Regions of necrosis (N) are
shown
Figure 4 (A) VEGF IHC in M006XLo xenograft (haematoxylin and eosin
counterstain, 103). (B) VEGF IHC control in M006XLo xenograft, neutralized
with tenfold excess of control peptide (103)DISCUSSION
The understanding of neoangiogenesis in glioblastoma multiforme
has advanced significantly in the last 4–5 years. Indeed, the pres-
ence of necrosis and vascular proliferation distinguishes glio-
blastoma multiforme from most other malignant brain tumours
including astrocytomas (Germano et al, 1989). Previous investiga-
tors (Plate et al, 1992; Shweiki et al, 1992) noted marked up-regu-
lation of VEGF expression in pallisading cells adjacent to necrosis
and also in other small anaplastic cells at some distance from
necrosis. It is now certain that in addition to hypoxic stress
(Shweiki et al, 1992; Damert et al, 1997), VEGF may be induced
by CoCl2 (Goldberg and Schneider, 1994); nitric oxide (Chin et al,
1997); tumour necrosis factor-a (TNF-a) (Ryuto et al, 1996);
glucose deprivation (Stein et al, 1995); platelet derived growth
factor-BB; transforming growth factor-b (TGF-b) (Brogi et al,
1994; Frank et al, 1995); and interleukin-1b (Li et al, 1995). The
presence of multiple metabolic and growth factor modulators of
this endothelial mitogen imply a complex in vivo regulation. In
contrast to the finding of co-localization of VEGF expression and
hypoxia using the marker EF5 in HT29 and EMT-6 spheroids
(Waleh et al, 1995), we found discordant results in several human
glioma lines grown as multicellular spheroids and xenografts.
Both VEGF ISH and IHC revealed virtually ubiquitous staining
regardless of the proximity to nutrient capillaries or necrosis
(Figures 3 and 4A, B). Only in a single xenograft tumour (M006X)
was there a suggestion of increased VEGF mRNA expression
adjacent to necrosis. Low power photomicrographs have been
used to emphasize general uniformity of both VEGF ISH and IHC
staining, with the ISH results confirmed by IHC.
Specific riboprobes that allow for the identification of the 121,
165, 189 and 206 amino acid isoforms of VEGF have been devel-
oped. The VEGF probe used in these studies, however, does not
distinguish between the various VEGF mRNA species. In cardiac
myocytes (Levy et al, 1995a), no significant changes in relative
isoform amounts were observed in response to hypoxic stress.
Given that the induction of VEGF mRNA species, using the probe
in our Northern analysis, results in the classically described picture
of VEGF mRNA induction with hypoxia, it is unlikely that the
absence of variations in expression of VEGF in situ is simply
related to changes in the proportions of isoforms without a change
in total transcript number.
The findings in the current models differ from those origi-
nally described (Shweiki et al, 1992) in patient-derived primary
biopsies. Every effort has been made to use glioma cell lines which
are preserved in an early passage stage after explantation
(Parliament et al, 1997). However, in situ oxygenation was not
assessed in the original study (Shweiki et al, 1992) of VEGF over-
expression; hypoxia was merely presumed to exist adjacent to
necrosis. To our knowledge, our data represent the first examina-
tion of the relationship between VEGF expression and hypoxia in
a solid glioma tumour model to date. A similar correlative study
would be possible in patients, but would require in situ hypoxia
marker labelling prior to biopsy (Urtasun et al, 1986). The hypoxic
fraction values obtained with the M006 xenografts for the comet
assay are close to those of the C3H murine mammary tumour under
air-breathing conditions (Olive et al, 1997) and are consistent with
our 3H-misonidazole data suggesting that most but not all M006
xenografts contain substantial radiobiological hypoxia.
The oxygen dependence of misonidazole binding is slightly
different from the hypoxic marker EF5 (Koch et al, 1995). EF5
shows less inhibition of binding at moderate oxygen tensions,
whereas misonidazole binding is inhibited by oxygen in a some-
what more complex fashion down to levels of hypoxia which
would be considered significant from the point of view of induc-
tion of radiation resistance (Chapman, 1984). In spheroids we have
also seen heterogeneous binding patterns of pimonidazole
(Kennedy et al, 1997), adjacent to the necrotic centres in a fashion
identical to that seen with misonidazole (AJ Franko, unpublished
data). Therefore, the findings in this study do not appear to be an
artifact of one particular hypoxia marker. Lack of correlation
between hypoxia marker binding and VEGF expression in
xenograft tumours is somewhat complex in that intratumoural drug
distribution may be suboptimal because of the aberrant tumoural
vasculature. However, glioma spheroids (Franko et al, 1998), in
which nitroimidazole drug penetration is not impaired, also reveal
substantial variation in hypoxia marker binding in the viable cells
adjacent to necrosis, a pattern similar to that seen in xenograft
tumours.
From the Northern analysis it is apparent that severe, patho-
physiological levels of hypoxia are not necessary for the up-regu-
lation of VEGF messenger RNA and protein expression; indeed
substantial upregulation is evident at modest levels of O2, which
would be similar to the physiological hypoxic conditions noted in
many mammalian organ systems. Our results are in agreement
with those of Leith and Michelson (1995) who showed that modest
hypoxia (i.e. 10% O2) is also sufficient to cause some induction of
VEGF expression in the clone A human colonic adenocarcinoma
cell line. VEGF production is known to be mediated by both
transcriptional and post-transcriptional mechanisms (Levy et al,
1995b, 1997). It is interesting to note that transcriptional regula-
tion of VEGF expression, through binding of the hypoxia-
inducible factor-1 (HIF-1) to a 28 bp site in the VEGF 5¢ promoter
(Wang et al, 1995; Jiang et al, 1996) also occurs at physiological
levels of hypoxia with half maximal response between 1.5 and 2%
O2 (Jiang et al, 1996). Post-transcriptional regulation of VEGF
mRNA levels appears to be due to reversible stabilization of
VEGF mRNA by hypoxia (Shima et al, 1995; Stein et al, 1995;
White et al, 1995; Levy et al, 1996). However, constitutive stabi-
lization of VEGF can occur through inactivation of the von
Hippel–Lindau tumour suppressor gene (Wizigmann-Voos et al,
1995; Gnarra et al, 1996; Iliopoulos et al, 1996; Levy et al, 1996).
We are currently investigating the possibility that such post-tran-
scriptional stabilization is involved in the constitutive expression
of VEGF by the lines M006XLo and M059K.
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Figure 5 VEGFR-1 (flt-1) IHC in M006XLo xenograft (haematoxylin and
eosin counterstain, 1003)The Northern blot data for M006X cells in vitro demonstrate
that VEGF expression is unregulated by 3.5-fold following a
reduction in pO2 from 18% to the more physiologically relevant
level of 6%. Furthermore, we have recently demonstrated IHC
detection of increased expression of VEGF protein in cultured
hypoxic (0.6 and 2% O2) M006X cells (Allalunis-Turner et al,
1999). In vitro, the percentage of M006X cell staining positively
by IHC for VEGF increased from 17% under fully oxygenated
conditions to 97% (under 2% O2). These data indicate that much of
the VEGF mRNA induction detected by Northern blotting is a
result of increase in the proportion of cells expressing VEGF
rather than a uniform increase in VEGF mRNA in most cells. A
change in staining pattern of this type would have been clearly
visible in the IHC of the spheroids and tumours. These data are
also compatible with the detection of VEGF mRNA and protein in
presumably well oxygenated tumour cells adjacent to blood
vessels in vivo. However, the Northern data do not provide an
explanation for the lack of an increase in VEGF expression with
increasing distance from blood vessels, and particularly the
absence in almost all tumours of elevated expression in severely
hypoxic cells adjacent to necrosis. An increase in expression by at
least fourfold (possibly eightfold) in the latter areas was predicted
by the Northern data, and clearly this was not observed. The
possible biological reasons for the disparity between our in vitro
and in vivo results require further investigation.
Up to 50% of the necrotic areas in M006 and M006XLo spher-
oids and M059K and M006 xenografts were reported to be well
oxygenated (Parliament et al, 1997; Franko et al, 1998), and those
observations are confirmed by the data reported here. The cause of
cell death in these regions has not been identified, although we
have postulated that it is related to glucose insufficiency (Franko
et al, 1998), which is known to up-regulate VEGF expression
(Stein et al, 1995). The absence of up-regulation of VEGF expres-
sion in cells adjacent to both aerobic and hypoxic necrosis
suggests that its regulation in glioma cells is remarkably resistant
to various types of microenvironmental stress.
Recently, a quantitative immunohistochemical comparison of
hypoxia and VEGF protein expression in squamous cell carci-
nomas of the uterine cervix and head and neck has been reported
(Raleigh et al, 1998). In this study in which patients received the
hypoxia marker pimonidazole prior to biopsy, no correlation was
seen between hypoxia and VEGF protein expression on quantita-
tive image analysis of histologic sections. The authors considered
the possibility that the lack of a correlation was a consequence of
the fact that the half-maximal inhibition of 2-nitroimidazole
binding by oxygen (0.4% gas-phase concentration) occurs at a
lower [O2] than half-maximal VEGF up-regulation (0.8–2.2% gas-
phase concentration) in mammalian cells. While this means that
pimonidazole labelling would not identify all cells capable of
inducing VEGF expression via a hypoxia-driven mechanism, the
authors argued that substantial gradients of VEGF expression
should have been observed in the cells separating blood vessels
and severely hypoxic cells. These were not observed, which lends
support to our observation that VEGF expression is independent of
hypoxia in these glioma models.
While one may speculate that cell lines overexpressing VEGF
when grown as tumours in vivo may achieve a growth advantage
because of a ‘pro-angiogenic’ phenotype, we have considered
another possible hypothesis. Reports of expression of VEGF recep-
tors KDR (Boocock et al, 1995; Liu et al, 1995) and flt-1 (Boocock
et al, 1995) have suggested a possible autocrine/paracrine growth
stimulation by VEGF in certain melanoma and ovarian carcinoma
lines. In view of this possibility, VEGFR-1 (flt-1) expression in the
M006XLo xenograft was analysed. Strong, widespread expression
of VEGFR-1 was detected in tumour cells. Previous studies
utilizing biopsies from patients with gliomas have reported only
tumour endothelial cell expression of VEGF receptors (Plate et al,
1994). Confirmatory studies are required to establish whether
autocrine stimulation of growth is occurring in these lines.
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